Key populations brief
Accessed November 2017
Time for recognition of lay counsellors
Accessed November 2017
Global Plan to end TB 2016-2020
Overcoming HIV-related stigma and discrimination in health- care settings and beyond
UNAIDS 2017 | REFERENCE
Expanded IMPACT Program in Zimbabwe
Lea Toto and APHIAplus Nuru ya Bonde programs in Kenya Yekokeb Berhan Program for Highly Vulnerable Children in Ethiopia
"This is the final report of the six-year collaboration between the WHO Department of Mental Health and Substance Abuse and the Gulbenkian Global Mental Health Platform, an initiative of the Calouste Gulbenkian Foundation aimed at reducing the global burden of mental health through the development a...nd application of evidence and good practices to global mental health."
more
BMJ,Dodd PJ, et al. Thorax 2017;72:559–575. doi:10.1136/thoraxjnl-2016-209421
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
Lessons from the STEP-TB Project.
Accessed November 2017.
National Tuberculosis and Leprosy Conrol Programme
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more